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Abstract
 
Stromal-derived factor (SDF)-1 and its G protein–coupled receptor, CXCR4, regulate stem/
progenitor cell migration and retention in the marrow and are required for hematopoiesis. We
show here an interaction between CXCR4 and the Src-related kinase, Lyn, in normal progeni-
tors. We demonstrate that CXCR4-dependent stimulation of Lyn is associated with the activa-
tion of phosphatidylinositol 3-kinase (PI3-kinase). This chemokine signaling, which involves a
Src-related kinase and PI3-kinase, appears to be a target for BCR/ABL, a fusion oncoprotein ex-
pressed only in leukemia cells. We show that the binding of phosphorylated BCR/ABL to Lyn
results in the constitutive activation of Lyn and PI3-kinase, along with a total loss of responsive-
ness of these kinases to SDF-1 stimulation. Inhibition of BCR/ABL tyrosine kinase with STI571
restores Lyn responsiveness to SDF-1 signaling. Thus, BCR/ABL perturbs Lyn function through
a tyrosine kinase-dependent mechanism. Accordingly, the blockade of Lyn tyrosine kinase inhib-
its both BCR/ABL-dependent and CXCR4-dependent cell movements. Our results demon-
strate, for the first time, that Lyn-mediated pathological crosstalk exists between BCR/ABL and
the CXCR4 pathway in leukemia cells, which disrupts chemokine signaling and chemotaxis,
and increases the ability of immature cells to escape from the marrow. These results define a Src
tyrosine kinases-dependent mechanism whereby BCR/ABL (and potentially other oncopro-
teins) dysregulates G protein–coupled receptor signaling and function of mammalian precursors.
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Introduction
 
The BCR/ABL oncogenic tyrosine kinase is responsible
for initiating and maintaining the leukemic phenotype of
chronic myelogenous leukemia (CML)
 
*
 
 cells. This onco-
protein is responsible for the phosphorylation, activation,
and dysregulation of intracellular signaling proteins that
regulate proliferation and survival of progenitor cells in
the marrow (1–4). The ability of immature leukemia cells
to leave the marrow and accumulate in high numbers in
blood and spleen suggests that the signaling events that
regulate migration and retention of progenitor cells in
marrow are also effected by this oncoprotein. Hemato-
poietic precursors need to be held in close contact to
bone marrow stromal cells for the extensive interactions
necessary for proper growth and maturation. Several tar-
gets of BCR/ABL, associated with integrin regulation,
such as focal adhesion proteins paxillin, talin, tensin, and
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FAK have already been identified (4, 5). It has been also
shown that CML cells fail to respond to at least two dif-
ferent chemokines: macrophage inflammatory protein
(MIP)-1
 
 
 
 and stromal-derived factor (SDF)-1 (6–8).
Chemokines are known to play an important role in reg-
ulating movement and retention of progenitor cells
within the bone marrow microenvironment. Intracellular
signaling pathways that mediate these effects are poorly
understood.
SDF-1 is a chemokine which acts through CXCR4,
the only known receptor for SDF-1 (9, 10). G protein–
coupled CXCR4 receptor, expressed on hematopoietic
cells, has been reported to mediate chemotaxis of CD34
 
 
 
stem cells, and to play a critical role in the homing of
these cells in the bone marrow microenvironment (11,
12). Mice lacking SDF-1 protein or the CXCR4 recep-
tor show lethal abnormalities in bone marrow my-
elopoiesis and B cell lymphopoiesis (13, 14). Recently,
SDF-1 was reported to function as both a chemoattrac-
tant and as a modulator of cellular growth/survival (15–
20). The phosphatidylinositol 3-kinase (PI3-kinase) and
RAS-to-MAPK pathways are essential routes through
which membrane-bound G protein–coupled receptors
convey either chemotactic, survival, or proliferative/dif-
ferentiative signals to the nucleus. Consequently, G pro-
tein–coupled CXCR4 receptor was reported to activate
the PI3-kinase and mitogenic MAPK cascade (15, 18,
21). The Src family kinases have been known to play a
key role in connecting G protein–coupled receptors to
RAS-activating proteins and MAPK (22–26). Interest-
ingly, a Src tyrosine kinase was recently shown to be a
novel direct effector of G proteins (27), and the direct
binding of activated c-Src to G protein–coupled recep-
tors was required for MAPK activation (28). Despite the
fact that the chemokine receptor, CXCR4, is known to
regulate the PI3-kinase and RAS-to-MAPK cascade, the
means by which this receptor couples to these signaling
cascades and modulates movement, survival, and prolifer-
ation remains unclear.
It was recently reported that BCR/ABL completely
blocks CXCR4-stimulated calcium flux and phosphoryla-
tion of p70 S6 kinase in hematopoietic transformed cells
(8). In this study, we show that BCR/ABL strongly acti-
vates a new CXCR4-dependent signaling component
through the Src family tyrosine kinase, Lyn. These oppos-
ing results indicate that the BCR/ABL oncoprotein alters
the chemotactic response to SDF-1 through a complex
mechanism involving both inhibitory and stimulatory ef-
fects on different signaling molecules. Crosstalk between
BCR/ABL and G protein–coupled CXCR4 signaling
through Lyn may allow this oncoprotein to couple simulta-
neously to PI3-kinase and the RAS-to-MAPK cascade and
to take over this chemokine pathway. Our results define a
molecular mechanism for the disruption of chemotaxis by
oncoproteins in hematopoietic progenitor cells, and poten-
tially, in other cellular systems. They also provide further
insight into the striking ability of Src family kinases to
transform mammalian cells.
 
Materials and Methods
 
Primary Cells and Cell Lines.
 
Bone marrow samples were ob-
tained from normal individuals and CML patients after informed
consent was obtained using guidelines approved by the Institu-
tional Review Board of the University of Pennsylvania. CD34
 
 
 
marrow cells were obtained from healthy individuals using im-
munoaffinity chromatography with magnetic beads (MACS
 
®
 
 cell
isolation kits; Miltenyi Biotec). Preparations were 
 
 
 
95% viable
CD34-expressing undifferentiated cells. Primary leukemic blasts
were isolated by apheresis and Percoll density gradient centrifuga-
tion (29) from patients with BCR/ABL-positive CML. Human
myeloid HL-60, Mo7e, and K562 cells were obtained from the
American Type Culture Collection. BCR/ABL tyrosine kinase
inhibitor STI 571 (Gleevec, imatinib mesylate) is currently
widely distributed by Novartis Pharmaceuticals Corporation. A
10 mM stock solution of STI 571 in distilled water was prepared
from which fresh working solutions were prepared in RPMI
1640 medium before the experiments. Cells were incubated in
fresh medium with or without 1 
 
 
 
M STI 571 for 20 h.
 
Animals.
 
Lyn-deficient and wild-type mice were maintained
in a pathogen-free environment at the National Cancer Institute-
Frederick. Animal care was provided in accordance with the pro-
cedures outlined in the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. Mice between the ages
of 8 and 12 wk were used for the study. Bone marrow was har-
vested from mouse femurs, and mononuclear cells were isolated
using Ficoll-Paque TM Plus (Amersham Pharmacia Biotech AB)
(36). Bone marrow–derived Lyn-deficient and wild-type mono-
nuclear cells were maintained in culture and evaluated with re-
gard to Lyn protein expression as described previously (36). It
was confirmed that cells derived from Lyn-deficient mice did not
express Lyn protein at all. In contrast, cells derived from wild-
type mice expressed high levels of Lyn protein (unpublished data).
 
Retroviral Production and HL-60 Infection Protocol.
 
The retrovi-
ral vectors MigR1 and Mig210 expressing the enhanced green
fluorescent protein (eGFP) and BCR/ABL proteins, respectively,
were gifts of W. Pear from the University of Pennsylvania, Phila-
delphia, PA. 293T cells were transfected with MigR1 or Mig-
210 using SuperFect Reagent (QIAGEN). The supernatant was
collected 48 h after transfection. The virus was titred against 3T3-
NIH cells. Subsequently, HL-60 cells were transduced by spinoc-
ulation and the infected cells were analyzed for the expression of
GFP by flow cytometry as described previously (30). GFP/BCR/
ABL positive HL60 cells were sorted with purity of 97%.
 
Immunoprecipitation and Reimmunoprecipitation Experiments.
 
Cells
were stimulated for various times with 100–300 ng/ml SDF-1
 
 
 
or SDF-1
 
 
 
 (UBI). After stimulation, cells were lysed with buffer
(0.8–2% NP-40, 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 30
mM sodium pyrophosphate, 50 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM
PMSF, 0.25 U/ml aprotinin, 10 
 
 
 
g/ml leupeptin, and 1 
 
 
 
M
pepstatin). Lysates (10 min on ice) containing identical amounts
of protein per sample were cleared by centrifugation, and then
incubated with the indicated antibody: anti-Lyn; anti-p85 PI3-
kinase; and anti-ABL SH2 domain (Upstate Biotechnology, Inc.)
for 4 h at 4
 
 
 
C. Preblocked pansorbin beads were added for 30
min, and washed twice with lysis buffer and once with 10 mM
Tris-HCl, pH 7.5, 100 mM NaCl, 0.1 mM Na
 
3
 
VO
 
4
 
. In vitro ki-
nase assays were performed directly on beads as we described pre-
viously (23). For secondary immunoprecipitation, Lyn immuno-
precipitates were washed twice to remove free ATP and the
beads were then boiled in 1 volume of 20 mM Tris-HCl, pH 8.0,
0.5% SDS, and 1 mM dithiothreitol to disrupt protein–protein
interaction, as previously described in detail (31). After centrifu- 
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gation, the diluted supernatant (after reducing the SDS concen-
tration to 0.1%) was reimmunoprecipitated with anti-ABL anti-
bodies. The secondary immunoprecipitates containing BCR/ABL
proteins were then washed in lysis buffer, boiled in sample buffer,
and loaded on 8% SDS-PAGE.
 
Assay for Lyn and BCR/ABL Kinase Activity.
 
A modifica-
tion of our previous protocol for Lyn kinase autophosphoryla-
tion was employed (23). To measure kinase activity of Lyn or
BCR/ABL, precipitates were washed as indicated and then in-
cubated in 25 mM Hepes, pH 7.1, 10 mM MnCl
 
2
 
, 1 
 
 
 
M ATP,
and 10 
 
 
 
Ci 
 
 
 
-
 
32
 
[P] ATP (6,000 
 
 
 
Ci/mmol; DuPont NEN). In
some experiments, 5 
 
 
 
g of acid-denaturated enolase was added
to the kinase reaction mixture as an exogenous substrate. Kinase
assays were performed at room temperature. The reaction was
stopped by the addition of 2
 
 
 
 Laemmli sample buffer and boil-
ing. Samples were analyzed by 8% SDS-PAGE, followed by au-
toradiography on Kodak X AR-5 film at –70
 
 
 
C, and quanti-
tated using densitometry.
 
Assay for PI3-Kinase Activity.
 
PI3-kinase activity was assayed
directly on beads of anti–PI3-kinase immunoprecipitates with an-
tibodies directed against the 85-kD regulatory subunit (Upstate
Biotechnology, Inc.). The reaction was performed for 10 min at
room temperature in a buffer containing 40 mM Hepes, pH 7.2,
6 mM MgCl
 
2
 
, and 1 mM EDTA, 20 
 
 
 
g of PI (Avanti Polar Lip-
ids), 10 
 
 
 
M ATP, and 10 
 
 
 
Ci 
 
 
 
-
 
32
 
[P] ATP (6,000 Ci/mmol;
DuPont NEN). 0.2 mM adenosine was added to the reaction
mixture to inhibit residual PI4-kinase activity. After incubation,
the reaction was stopped with methanol plus 2.4 N HCl, 1/1
(vol/vol), lipids were extracted, analyzed by thin-layer chroma-
tography, and then quantified as we described earlier (32).
 
Chemotaxis Assay.
 
SDF-1–induced chemotaxis of BCR/
ABL-negative HL-60 cells (MigR1) and their BCR/ABL-trans-
formed counterpart (Mig210) was determined in six independent
experiments with Costar Transwell cell culture chambers accord-
ing to the manufacturer’s recommendations (Corning Inc.). HL-
60 cells (both MigR1 and Mig210) were preincubated for 17 h in
serum-free medium (RPMI 1640) in 37
 
 
 
C. Subsequently, cells
were incubated for 30 min in the presence or the absence of 10
 
 
 
M PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-
d]pyramidine) (Calbiochem) before stimulation with SDF-1
(Upstate Biotechnology, Inc.). This concentration of PP2 was
found to be effective in inhibiting Lyn activity in our preliminary
dose–response experiments. Cells were tested for their ability to
migrate in response to medium with SDF-1 (100–300 ng/ml) or
medium alone for 1–3 h at 37
 
 
 
C. Migrating cells monolayers
were fixed and stained using standard cytological techniques
(Wright-Giemsa), and subsequently cells were counted. Growth
factor–dependent cell line Mo7e, grown in DMEM with 500 ng/
ml GM-CSF, was used as an additional control. These cells were
preincubated for 2.5 h in GM-CSF–deficient media before treat-
ment with PP2, stimulation with SDF-1 and chemotaxis assay.
Bone marrow–derived CD34-positive cells were preincubated
for 2.5 h in serum-free Iscove modified Dulbecco medium
(IMDM; JRH Biosciences) before treatment for 30 min with 10
mM PP2 or its inactive analogue PP3 (4-amino-7-phenylpyra-
zol[3,4-d]pyramidyne) (Calbiochem), stimulation with 200 ng/
ml SDF-1 or 100 ng/ml PMA (Sigma-Aldrich) and chemotaxis
assay. PP3 and PMA were used as controls for PP2 and SDF-1,
respectively. Bone marrow–derived Lyn-deficient and wild-type
mononuclear cells were isolated, maintained in culture, and eval-
uated with regard to Lyn protein expression as described previ-
ously (36). These cells were preincubated for 2.5 h in serum-free
IMDM (JRH Biosciences) before stimulation with 200 ng/ml
SDF-1 or 100 ng/ml phorbol PMA (Sigma-Aldrich) and chemo-
taxis assay. In all chemotactic experiments, inserts were loaded
with 100 
 
 
 
l of medium containing 50,000–100,000 cells (input
population). The transmigrated cells which were visible in six
randomly selected fields were counted (in different experiments,
the number of control unstimulated transmigrating cells was 299–
700 in six fields, which is represented as 100% on our figures).
 
Results
 
SDF-1 Regulates the Activity of the Lyn Protein Tyrosine
Kinase in Hematopoietic Cells.
 
The chemokine receptor
CXCR4 and its ligand, SDF-1, not only regulate move-
ment (11, 12, 15), but are also able to modulate hemato-
poietic cell proliferation and survival (16–20). To evaluate
the possible role of nonreceptor Src family tyrosine kinases
in the movement, proliferation, and survival process, we
screened SDF-1–stimulated CD34
 
 
 
 
 
progenitor cells, and
HL-60 cells which have been shown to express CXCR4
on their surface (33), for the activities of known Src-like
kinases. We observed that the activity of the Lyn tyrosine
kinase was significantly increased in SDF-1–stimulated my-
eloid cells, as recently reported in Jurkat T cells (34). Fig. 1
shows a representative time course for Lyn activation by
SDF-1 in HL-60 cells (A) and CD34
 
 
 
 
 
primary cells (B).
Both Lyn autophosphorylation and its ability to stimulate
phosphorylation of the exogenous substrate protein enolase
increased within minutes of SDF-1 stimulation with maxi-
mum activity being detected after 5 min. Lyn activity de-
Figure 1. SDF-1 stimulates Lyn kinase activity in hematopoietic cells.
(A) Lyn autophosphorylation is increased after treatment of HL-60 cells
with SDF-1; SDF-1 induces an increase in Lyn phosphorylation of sub-
strate enolase. A similar time course was obtained using SCF as a positive
control. (B) Lyn and enolase phosphorylation are stimulated after treat-
ment of CD34  marrow progenitors with SDF-1. Cells in all experi-
ments were stimulated for the indicated times with either SDF-1 or SCF,
lysed, and immunoprecipitated with anti-Lyn antibodies. Immune com-
plex in vitro kinase assays were performed as described in Materials and
Methods. The changes in Lyn autophosphorylation are indicated (by fold
increase) based on the densitometry. The results shown are representative
of two experiments. 
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clined slowly after the 5–10 min peak and returned to base-
line levels after 60 min. Two major isoforms of Lyn, 53 kD
and 56 kD, are formed due to alternative splicing (35). Au-
tophosphorylation of both isoforms was detected in HL-60
cells and the more abundant 53-kD form was detectable in
CD 34
 
 
 
 primary bone marrow cells. There was no change
in the actual levels of Lyn proteins during the SDF-1 treat-
ment of HL-60 or CD34
 
 
 
 cells, as determined by Western
blot analysis (unpublished data). The stem cell factor/kit
ligand (SCF/KL), a cytokine critical for normal hemato-
poiesis, is known to activate Lyn in hematopoietic progen-
itor cells (36). Therefore, stimulation with SCF/KL was
used as a positive control in the kinase assays. Fig. 1 A
shows a representative time course for Lyn activation in-
duced by SCF/KL in HL-60 cells. Results obtained were
similar to those obtained with SDF-1 stimulation. These
results indicate that SDF-1 and SCF/KL share the Lyn sig-
naling pathway in hematopoietic cells. Interestingly, SCF/
KL has been recently reported to enhance chemotaxis in-
duced by SDF-1. Also, cooperativity in downstream signal-
ing pathways, including MAPK, has been demonstrated
with SDF-1 in combination with SCF/KL (37).
 
SDF-1 Regulates the Activity of the PI3-Kinase in Hemato-
poietic Cells.
 
The Lyn activation time course described
above correlates with some of the earliest signaling events
known to occur after SDF-1 stimulation. In particular, it
corresponds to the previously observed time course for
PI3-kinase activation (21). We detected an SDF-1 induced
increase of PI3-kinase activity in p85 immunoprecipitates
as reported previously (15, 21). Fig. 2, A and B shows a
representative time course for PI3-kinase activation by the
CXCR4 receptor in HL-60 and CD34
 
 
 
 precursor cells.
PI3-kinase activity increased in p85 immunoprecipitates
within minutes, with maximum activity occurring be-
Figure 2. SDF-1 stimulates PI3-kinase activity in hematopoietic cells. (A) Cellular p85 subunit-dependent PI3-kinase activity is increased after SDF-1
treatment of HL-60 cells. (B) Cellular p85 subunit-dependent PI3-kinase activity is stimulated after SDF-1 treatment of CD34  bone marrow progeni-
tors. (C) Lyn-associated PI3-kinase activity is increased in SDF-1–stimulated HL-60 cells. Cells were stimulated for the indicated times with SDF-1,
lysed, and immunoprecipitated with anti-PI3-kinase p85 antibodies (A, B, and C-a 1), anti-Lyn antibodies (2C-a, 2-5, and 2C-b), or control anti-Lck
antibodies. PI3-kinase activity was measured in immunoprecipitates as described in Materials and Methods. The indicated changes in PIP are based on
densitometry values. Aliquots of total cell lysates were subjected to either Lyn immunoprecipitation and immunoblotting with anti-p85PI3K Ab or immu-
noblotting with anti-Lyn ab Similar amounts of Lyn protein were present in stimulated and control cells (C-b). The results shown are representative of
two experiments. 
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tween 5 and 10 min. Given that concurrent activation of
PI3-kinase and Lyn was detected, we asked whether these
kinases could physically associate in SDF-1–stimulated
cells. Lyn has been shown to couple (directly or indirectly)
to p85 subunit-dependent PI3-kinase in B lymphocytes ac-
tivated through the B cell antigen receptor (38), in hu-
man neutrophils activated through the 
 
N
 
-formyl peptide
chemoattractant G protein–coupled receptor (23), in hu-
man monocytes stimulated with bacterial lipopolysaccha-
ride via the CD14 receptor (39), and in human platelets ac-
tivated through the thrombin receptor (40). A relatively
small proportion of cellular PI3-kinase, that which is ty-
rosine phosphorylated, binds to the SH2 domain of acti-
vated Src-related kinases (31). Accordingly, only slight co-
precipitation of p53/56 Lyn and p85-PI 3-kinase was
demonstrated by simple IP and subsequent immunoblot-
ting in our experiments (Fig. 2 C-b). Thus, a more sensi-
tive technique was chosen wherein Lyn immunoprecipi-
tates were directly subjected to an in vitro PI3-kinase assay.
We detected PI3-kinase activity in Lyn immunoprecipi-
tates from SDF-1–stimulated cells (Fig. 2 C-a). In contrast,
we observed no PI-kinase activity in control immunopre-
cipitates with Lck antibody, ruling out nonspecific binding
as a possible source of PI3-kinase activity. The amount of
PI3-kinase activity specifically associated with Lyn was
 
 
 
10% of the total activity measured in p85 subunit anti-
body precipitates. The time course of Lyn-associated PI3-
kinase activity corresponded to that of Lyn tyrosine kinase
activity (Fig. 1, A and B) as well as for total cellular PI3-
kinase activation (Fig. 2, A and B). These data indicate
that a link exists between Lyn and PI3-kinase activation in
SDF-1–stimulated hematopoietic cells.
 
Defect in the SDF-1–induced Lyn/PI3-Kinase Pathway in
CML.
 
Previous studies have shown that BCR/ABL
forms complexes with Src-related kinases in IL-3–depen-
dent myeloid murine cell lines (41). To determine whether
these signaling complexes can perturb G protein–coupled
CXCR4 chemokine receptor-regulated pathways, we per-
formed several experiments in human hematopoietic cells,
which are described below.
As Lyn and PI3-kinase are regulated by SDF-1 in normal
hematopoietic cells, we evaluated the effect of SDF-1 on
Lyn and PI3-kinase activity in BCR/ABL-positive blasts of
CML patients
 
.
 
 For direct comparison, we used material
from the same patients for both Lyn and PI3-kinase experi-
ments. Portions from the same cell cultures were treated
with SDF-1 and used for either Lyn or PI3-kinase analysis.
Both Lyn and PI3-kinase were highly active in blasts from
all CML patients (4 out of 4 patients). Basal activity of Lyn
and PI3-kinase increased by several fold in leukemic blasts
as compared with progenitor CD34
 
 
 
 cells derived from the
bone marrow of healthy individuals. Moreover, the activity
of the kinases did not increase in SDF-1– treated blasts
(Fig. 3, A and B) as compared with normal cells (Fig. 1 B
and Fig. 2 B). We conclude that both Lyn and PI3-kinase
are constitutively active, and thus insensitive to stimulation
through CXCR4 in transformed, as opposed to normal
progenitor cells.
The use of primary cells can be problematic due to their
limited viability in vitro, limited sample size and patient
variation. Hence, we also used a myeloid human cell line
to relate our findings to CML phenotype. HL-60 cells nor-
mally do not contain the Philadelphia chromosome and are
thus BCR/ABL-negative. Therefore, these cells were in-
fected with a retroviral vector coexpressing p210 BCR/
ABL and GFP as described previously (30). After infection,
green positive cells were sorted by FACS
 
®
 
 yielding a
 
 
 
95% pure GFP-positive cell population. Immunoblotting
and in vitro kinase assays were performed to confirm the
expression and enzymatic activity of the kinase. Infected
HL-60 cells possessed high levels of protein expression and
tyrosine kinase activity of the expected 210-kD BCR/ABL
protein (Fig. 3 C).
We evaluated BCR-ABL protein expression and its ty-
rosine kinase activity in infected HL-60 cells by Western
blot and an immune complex in vitro kinase assay. We ob-
served the presence of a p56/53-kD tyrosine phosphory-
lated protein in BCR-ABL precipitates (Fig. 3 C). This
presence was detectable only in Mig210 BCR/ABL-posi-
tive cells, but not in control-vector infected MigR1 cells.
The possible association of BCR/ABL with Lyn was fur-
ther probed by looking for the presence of BCR/ABL in
Lyn immunoprecipitates. Fig. 3 D shows that we could
precipitate phosphorylated 210-kD protein with the anti-
Lyn antibody and that this association took place only in
BCR/ABL-infected HL-60 cells (Mig210). The phosphor-
ylated 210-kD protein comigrated with BCR/ABL in the
positive control (BCR/ABL-positive K562 cell line). Lev-
els of tyrosine phosphorylation of Lyn and other associated
proteins were elevated in the BCR/ABL-positive cells as
compared with control cells.
Since the p210 and p56/53 proteins were detected in
Lyn and BCR/ABL precipitates, respectively, it strongly
suggested that constitutively phosphorylated BCR/ABL
couples to Src-related kinase Lyn in transformed human
cells. The identity of the 210-kD protein as BCR/ABL
was confirmed by reimmunoprecipitating the Lyn precipi-
tates with anti-ABL antibody. For this purpose, Lyn immu-
noprecipitates from Mig210 and MigR1 cells were sub-
jected to in vitro kinase assays, treated with disruption
buffer to dissociate protein complexes, and subsequently
reprecipitated with anti-ABL antibodies as described previ-
ously (31, 41). Fig. 3 D-a shows that we could specifically
reprecipitate phosphorylated 210-kD protein with anti
ABL-antibodies and that this precipitation occurred in
BCR/ABL-infected, Mig210, but not in control, MigR1
cells. The reimmunoprecipitated protein comigrated with
p210 BCR/ABL, isolated through anti-ABL immunopre-
cipitates of control K562 cells. These results directly show
that the p210 protein in Lyn immune complexes from hu-
man hematopoietic cells is BCR/ABL.
Lyn and PI3-kinase were shown to be excessively active
in CML blasts (Fig. 3, A and B). Therefore, it was of inter-
est to measure whether activities of these kinases were up-
regulated in BCR/ABL-infected HL-60 cells. Infection of
cells did not alter Lyn and PI3-kinase protein levels, as de- 
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termined by Western blot analysis (Fig. 3, E and F). How-
ever, basal enzymatic activities of Lyn and PI3-kinase were
increased by an average of fivefold and threefold, respec-
tively, in BCR/ABL-infected cells as compared with con-
trol cells. (Fig. 3, E and F). Consequently, SDF-1 had no
significant effect on Lyn and PI3-kinases activities in BCR/
ABL-positive cells. This was in contrast to control cells,
which showed clear time-dependent changes for Lyn and
PI3-kinase activities after SDF-1 stimulation. These find-
ings suggest that BCR/ABL tyrosine kinase activity per-
turbs the SDF-1–regulated Lyn transduction pathway in
hematopoietic transformed cells. To make certain that the
Figure 3. Defect of SDF-1–induced Lyn/PI3-kinase pathway in chronic myeloid leukemia. (A and
B) Representative time course of Lyn and p85-dependent PI3-kinase phosphorylation in SDF-1–
stimulated BCR/ABL-positive leukemic blasts (CML). Lyn tyrosine kinase activity (A) and PI3-kinase
activity (B) are not increased after SDF-1 stimulation. This is in contrast to time courses observed
in normal CD34  cells and BCR/ABL-negative HL-60 cells, which are presented in Fig. 1, 2, and 3,
E and F. Results are representative of four experiments. (C) Expression of exogenous BCR/ABL in
HL-60 cells. Infected cells were analyzed for protein levels of exogenous BCR/ABL by Western blot
and for BCR/ABL tyrosine kinase activity by immune complex in vitro kinase assays, as described in
Materials and Methods. P56/53-kD tyrosine phosphorylated protein is detectable in BCR/ABL pre-
cipitates from BCR/ABL-infected Mig210 cells, but not from cells infected with control vector
(MigR1). (D) Expression of endogenous Lyn in BCR/ABL-infected HL-60 cells. P210-kD tyrosine
phosphorylated protein is coimmunoprecipitated with anti-Lyn antibody in Mig210, but not MigR1
cells. This protein comigrates with endogenous BCR/ABL in K562 cells (positive control). The
phosphorylated 210-kD protein was identified as BCR/ABL by secondary p210 BCR/ABL immu-
noprecipitations on primary Lyn precipitates. The secondary IPs were performed after the disruption
of protein complexes by disruption buffer (see Material and Methods). The position of BCR/ABL is
indicated by the arrow. The relatively weak signal from secondary IPs is explained by the loss of pre-
cipitated proteins during disruption and reprecipitation. Results are representative of two experiments
(D-a). (E and F) Comparison of SDF-1–stimulated Lyn and PI3-kinase activities and protein levels in
BCR/ABL-negative HL-60 cells and BCR/ABL-positive HL-60 cells. Lyn autophosphorylation is
inducible by SDF-1 in MigR1, but not in Mig210 cells (E). P85 subunit-dependent PI3-kinase activ-
ity is stimulated by SDF-1 in control cells, but not in Mig210 cells (F). 
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observed alteration in Lyn and PI3-kinase activities are
caused by BCR/ABL tyrosine kinase-dependent mecha-
nism, we measured Lyn and PI3-kinases activation in STI
571-pretreated cells. STI 571 is a protein-tyrosine kinase
inhibitor that strongly inhibits the BCR/ABL tyrosine ki-
nase, and is well selective (42). As shown in Fig. 4, A and
B, pretreatment of Mig210 cells with STI 571 partially re-
stores Lyn and PI3-kinase responsiveness to SDF-1. Thus,
CXCR4 receptor cannot regulate Lyn and PI3-kinase in
BCR/ABL-transformed cells apparently due to perturba-
tions caused by tyrosine kinase activity of this oncoprotein.
 
Src Family Tyrosine Kinase Pathway Is Required for both
SDF-1–dependent and BCR/ABL-dependent Hematopoietic
Cell Movements.
 
It was previously established that Lyn is
required for normal stem cell factor-induced chemotaxis of
primary hematopoietic cells in mice (36). To address the
question of the involvement of Lyn in CXCR4-regulated
chemotaxis in BCR/ABL-positive and BCR/ABL-nega-
tive control cells, we examined the effect of pyrazolopirim-
idine PP2 on SDF-1–induced chemotaxis. PP2 was de-
signed and synthesized for inhibition of Src family kinases
and appeared to be selective for these kinases (43). We
confirmed that PP2 effectively inhibited tyrosine phos-
phorylation of Lyn at concentrations from 0.1 to 10
 
  
 
M.
In the presence of 0.1 and 1 
 
 
 
M PP2, Lyn phosphorylation
was blunted by 74 and 90%, respectively, with 100% inhi-
bition seen at 10 
 
 
 
M (unpublished data). Indeed, if the
decrease in Lyn-stimulated phosphorylation of enolase is
considered, the level of inhibition is even greater (100% in-
hibition seen at 1 
 
 
 
M PP2) (unpublished data). This is sim-
ilar to the effective in vivo doses of PP2 reported in the lit-
erature for Src family kinases (43).
As shown in Fig. 5 A the initial number of BCR/ABL-
negative MigR1 cells that migrated to medium alone was
arbitrarily set to 100%. The number of MigR1 cells that
migrated to medium plus SDF-1 was approximately five-
fold higher. Similar results were obtained using another
Lyn-expressing (unpublished data), BCR/ABL-negative
hematopoietic cell line, M07e (Fig. 5 B). In contrast,
BCR/ABL-positive Mig210 cells had a strong chemotactic
response to both medium alone or medium plus SDF-1.
The presence of SDF-1 in the medium had no significant
effect on Mig210 cell migration. This result indicates that
BCR/ABL oncoprotein blocks CXCR4-regulated chemo-
taxis, but increases spontaneous cell motility. Chemotaxis,
both CXCR4-dependent (in MigR1 or M07e cells) and
BCR/ABL-dependent (in Mig210 cells), was effectively
blocked by PP2 pretreatment. It indicates that a Src family
kinase is required for chemotaxis and is shared between
CXCR4 signaling and BCR/ABL signaling in hematopoi-
etic cells. These results are highly consistent with participa-
tion of Lyn in BCR/ABL and CXCR4 signal transduction
as demonstrated in Figs. 1–4.
We demonstrated using both BCR/ABL gene transfer
and the BCR/ABL inhibitor STI-571, that BCR/ABL se-
verely perturbs CXCR4-regulated Lyn signaling pathway
and cellular migration (Figs. 3 E, 4 A, and 5 A). The speci-
ficity and relevance of Lyn and other Src-family kinases to
Figure 4. Effect of STI-571 on SDF-1–regulated Lyn/PI3-kinase path-
way in BCR/ABL-positive cells. (A) Comparison of SDF-1–stimulated
Lyn activity and protein levels in BCR/ABL-positive HL-60 cells ex-
posed or not exposed to 1.0  M STI-571. (B) Comparison of SDF-1–
stimulated PI3-kinase activity and protein levels in BCR/ABL-positive
HL-60 cells exposed or not exposed to 1.0  M STI-571. The changes in
Lyn or PI3-kinase phosphorylation are indicated (by fold increase) based
on the densitometry. 
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hematopoietic cell migration is a complex issue which is
further addressed here. The specificity of the Src-family ki-
nase-requiring SDF-1 pathway is indicated by the data we
obtained with primary human stem/progenitor cells. We
showed that PP2, a specific inhibitor of Src family kinases,
but not PP3, an inactive analoque of PP2 (43), inhibits the
effects of SDF-1 in CD 34
 
 
 
 cells (Fig. 5 C). To further
demonstrate that the blockade of migration in PP2-treated
CD34
 
 
 
 
 
cells was specific for SDF-1 signaling and Src ki-
nases, we examined migration in response to PMA. PMA is
a direct activator of the protein kinase C signaling pathway
that works separately from the Src-family kinases. Fig. 5 C
shows that, in contrast to SDF-1-induced migration,
PMA-induced migration was not inhibited at all in PP2-
treated CD34
 
 
 
 human cells. By using PP3 and PMA, we
showed that PP2 did not exert any nonspecific effects on
chemotactic signaling or cytotoxic effects that could ac-
count for some of the blockade of SDF-1–regulated migra-
tion. Thus, the inhibitory effect of PP2 on cellular migra-
tion was due to the specific blockade of Src-family kinases.
Since PP2 acts on a broad range of Src-family kinases, it
is possible that other Src kinases are also involved in the
interactions shown for Lyn. To make certain that Lyn is
important for SDF-1-regulated migration, we measured
the effect of SDF-1 on Lyn-deficient mononuclear cells
derived from marrow of knock-out mice (36). Although
SDF-1 increased migration of wild-type mice-derived
cells by an average of sixfold, these increases were blunted
in Lyn-deficient mice-derived cells by 77.7% (Fig. 5 D).
Thus, cellular migration was inhibited by nearly 80% in
Lyn-deficient cells, indicating that the Lyn pathway is
quantitatively predominant for SDF-1–regulated hemato-
poietic cell migration. PMA-induced migration was not
inhibited in Lyn-deficient cells ruling out cytotoxic effects
that could account for the inhibition of migration. Lyn
deficiency did not completely prevent SDF-1–induced
migration. It is possible that other Src-related kinases are
able to partially compensate for the loss of Lyn in knock-
out mice. Multiple Src-family kinases are able to compen-
sate for the loss of one related kinase (58, 59). In conclu-
sion, the data we generated using both pharmacological
and genetic approaches showed that Lyn-requiring path-
way is important for hematopoietic cell migration during
stimulation by SDF-1. Since Lyn is stimulated by BCR/
ABL oncoprotein in leukemia cells, these cells confuse sig-
nals from BCR/ABL as signals from a chemokine recep-
Figure 5. Effect of PP2 on CXCR4-dependent and
BCR/ABL-dependent cell movements. Inhibition of
CXCR4-dependent cell movements in Lyn-deficient pri-
mary cells. (A) The inhibition of SDF-1–regulated chemo-
taxis by PP2 was determined as described under Materials
and Methods and Results in BCR/ABL-negative HL-60
cells (MigR1) and BCR/ABL-positive HL-60 cells
(Mig210). The initial number of BCR/ABL-negative
MigR1 cells that migrated to medium alone was set to
100%. The results shown (mean   SD) are averages of six
experiments. (B) The inhibition of SDF-1–regulated
chemotaxis by PP2 was determined in hematopoietic pre-
cursor cells Mo7e as described under Materials and Meth-
ods and Results. The results shown are representative of six
experiments. (C) The suppression of CXCR4-dependent
chemotaxis by PP2, but not by its inactive analogue PP3,
in CD34  human primary myeloid cells. PMA-induced
migration is normal in PP2-pretreated CD34  cells. Treat-
ment and migration were performed as described in Mate-
rials and Methods. The results shown represent the aver-
age   range of four separate determinations with different
normal cell donors. (D) The reduction of SDF-1-induced
migration in Lyn-deficient mononuclear bone marrow
cells from knock-out mice. PMA-induced migration ap-
pears to be normal in these cells. Data represents the mean
and standard deviation of eight samples with eight different
animals. Treatment with factors and migration assays were
performed as described in Materials and Methods. 
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tor. This results in inappropriate, receptor-independent
cell migration.
 
Discussion
 
In this work, we show a direct functional and physical
association between the oncogenic BCR/ABL tyrosine ki-
nase, Src-related tyrosine kinase, Lyn, and the CXCR4 G
protein-coupled receptor-induced chemokine pathway in
hematopoietic cells. The Lyn tyrosine kinase is rapidly and
transiently activated in SDF-1–stimulated normal hemato-
poietic cells as well as in the BCR/ABL-negative HL-60
cell line. However, BCR/ABL-positive leukemic blasts of
CML patients and BCR/ABL-infected HL-60 cells dem-
onstrate constitutive Lyn activity. Lyn, and the Lyn-associ-
ated PI3-kinase, are not SDF-1 responsive in these cells.
The regulatory effect of SDF-1 on Lyn and PI3-kinase is
restored in STI-571–treated cells indicating that BCR/
ABL interacts with G protein-coupled CXCR4 signaling
in a tyrosine kinase-dependent manner. As a further indica-
tion of the involvement of BCR/ABL in CXCR4 signal-
ing, we also observed a physical association between BCR/
ABL and Lyn. Thus, we demonstrate for the first time that
BCR/ABL perturbs, via Lyn, a CXCR4-regulated path-
way. While the binding of BCR/ABL to Src family kinases
has been reported previously (41), to the best of our
knowledge it has not been reported that this interaction al-
ters the G protein–coupled chemokine receptor signaling
pathways. On first examination our results seem to be in
contrast to the data of Salgia et al. (8), who showed that
BCR/ABL strongly blocks, but does not activate, CXCR4
regulated calcium flux and p70 S6 kinase phosphorylation
in transformed cells. However, since Lyn and PI3-kinase
are directly associated with and strongly activated by BCR/
ABL, it is possible that Lyn and PI3-kinase are simply se-
questered by this oncoprotein. Without sufficient amounts
of these signaling proteins for use by CXCR4, SDF-1 sig-
naling would be shut down. Since we also show that Lyn
and PI3-kinase are continuously activated by BCR/ABL,
from inside of the cell, it is possible that the paradoxical
cellular responses we describe in BCR/ABL-transformed
cells, e.g., reduced chemotactic response to SDF-1 accom-
panied by increased spontaneous motility (Fig. 5), could re-
sult. Since Lyn is a target for both BCR/ABL oncoprotein
and CXCR4 receptor, hematopoietic cells may “mistake”
signals from BCR/ABL as signals from the CXCR4
chemokine receptor. This could lead to inappropriate cell
migration in CML and explain this long-observed phe-
nomenon. Our findings, along with those of Salgia et al.
(8), are of particular interest since they provide a plausible
explanation for some of the homing and retention defects
characteristic of leukemia, (i.e., the ability of CML cells to
leave the marrow, circulate in high numbers in the blood,
and infiltrate other tissues).
Effectors involved in SDF-1–induced PI3-kinase activa-
tion and RAS-to-MAPK activation are currently un-
known. The data presented here imply a mechanism that
explains the ability of the G protein–coupled CXCR4 re-
ceptor and BCR/ABL oncoprotein to stimulate many in-
tracellular signaling cascades, which were described previ-
ously in normal and malignant hematopoietic cells (4, 15,
21, 23). Different G protein–coupled signaling pathways
synergize with other receptor pathways to enhance or in-
hibit signals elicited by these various receptors. Numerous
reports describe Src as a go-between that relays messages
from G protein–coupled receptors to the growth factor re-
ceptor tyrosine kinase signaling complex (22, 23, 26, 44). It
has been suggested that the Src-related tyrosine kinase Lyn
is a signaling intermediate between G protein-coupled
chemoattractant receptors and PI3-kinase as well as the
RAS-to-MAPK pathway in human neutrophils and eo-
sinophils (23, 32, 45). Analogous roles for Src family mem-
bers were proposed in other cell types (24–26, 28, 39–40).
Since we have found that Lyn and PI3-kinase are stimu-
lated by SDF-1 and are physically associated, it is logical to
suggest a similar role for Lyn in signal propagation from the
G protein–coupled CXCR4 chemokine receptor to PI3-
kinase and RAS-to-MAPK activation in normal hemato-
poietic cells. Since we also have demonstrated that Lyn is a
direct signaling target for BCR/ABL in transformed cells, it
is reasonable to propose an analogous role for Lyn in signal
transmission from BCR/ABL to PI3-kinase and RAS/
MAPK. At the present time, it would be difficult to accept
the notion that activation of PI3-kinase by BCR/ABL oc-
curs exclusively through Lyn. There are a several of other
pathways proposed in the past through which this oncopro-
Figure 6. Proposed model for interaction between oncoproteins and G
protein-coupled signal transduction pathways in transformed mammalian
cells. BCR/ABL oncoprotein interferes with the Src-related kinase Lyn
signaling, which is regulated by G protein–coupled chemokine receptors
in hematopoietic cells. A previously defined direct interaction of G pro-
tein subunits with Src family kinases (references 24 and 27) and linkage of
G protein–coupled receptor via Src kinases to the receptor tyrosine kinase
complex and its downstream signaling cascades (references 22–28 and 44)
is indicated, as described in the text. The signaling paradigm we have de-
picted provides a mechanism to explain the ability of BCR/ABL, and po-
tentially other oncoproteins, to couple simultaneously to multiple signal-
ing transducers (e.g., PI3-kinase, Shc adaptor protein, receptor tyrosine
kinase, and the RAS-to-MAPK cascade). This paradigm may also provide
further insight into the remarkable ability of Src family kinases to trans-
form various cell types. 
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tein could potentially activate PI3-kinase (46, 47). In any
event, according to our present model, both the CXCR4
G protein-coupled receptor and BCR/ABL oncoprotein
may gain access to intracellular cascades through Src-related
tyrosine kinase Lyn in progenitor hematopoietic cells (Fig.
6). This signaling paradigm would be consistent with our
present data and with the previous observation of Hallek et
al. (46), who discovered that the signaling complex of re-
ceptor tyrosine kinase p145c-kit can be activated by the
p210 BCR/ABL oncoprotein in hematopoietic cells. Lyn
associates with the juxtamembrane region of the c-kit re-
ceptor (48). This receptor is critical in the movement, pro-
liferation, and survival of hematopoietic progenitor cells
(36). Nonetheless, we do not dispute the possibility that
other than Src kinases-dependent crosstalk pathways might
also exist. This is the legitimate object of additional studies.
In addition to our present results, alteration of Lyn/PI3-
kinases’ activities may be relevant to the pathogenesis of hu-
man leukemia for the following reasons: (i) we described
several years ago a key role for Lyn kinase in propagation
signals from G protein–coupled chemoattractant receptors
to p85 subunit-dependent PI3-kinase, Shc/RAS-to-MAPK
pathway, and to the interior of blood cells (23, 32). Then,
we proposed that G protein–coupled chemoattractant re-
ceptors crosstalk to tyrosine phosphorylation signaling
through Lyn. It was shown recently, in Lyn-deficient mice,
that Lyn is also required for normal stem cell factor–regu-
lated chemotaxis and proliferation in progenitor hemato-
poietic cells (36). Moreover, regulation of Lyn phosphory-
lation is an important antiapoptotic event in blood cells
(49). These findings suggest that Lyn is a signaling element
that brings chemotaxis, proliferation, and survival to a point
of convergence in developing hematopoietic cells. Src-fam-
ily tyrosine kinases are a major group of cellular signal trans-
ducers that are involved in proliferation/survival and onco-
genity in various tissues. In fact, c-Src was the first identified
protein tyrosine kinase and the first oncogene identified (50,
51). Tyrosine kinases of the Src family play a critical role in
crosstalk between G protein–coupled receptors, integrins,
and tyrosine kinase growth factor signaling. Src family ki-
nases pleiotropically link these receptors to the mitogenic
MAPK cascade, which may provide an oncogenicity mech-
anism (23, 26). (ii) PI3-kinase, which is often physically
and/or functionally associated with Src-family tyrosine ki-
nases, is an important regulator of progenitor mammalian
cells movement, differentiation, proliferation, and survival
(52, 53), and is also able to transform cells (54). A new on-
cogene derived from the p85 regulatory subunit of PI3-
kinase was recently identified (55). This oncogene is re-
sponsible for the malignant transformation of lymphoid cells
in mice. In addition, it was shown that the gene encoding
the catalytic subunit of PI3-kinase is also able to transform
cells (56). It was previously demonstrated that PI3-kinase is
a downstream effector of ABL oncogenic variants (57). The
p85 subunit-dependent PI3-kinase plays a major role in the
BCR/ABL-induced proliferation and survival of CML cells
(47). Thus, a constitutive activation of PI3-kinase that ap-
pears simultaneously with excessive Lyn activity in BCR/
ABL-positive hematopoietic cells could potentially play im-
portant role in the pathogenesis of CML, or at the least in
determining the malignant phenotype.
In conclusion, we describe the CXCR4-unregulatable
Lyn and PI3-kinase activities in BCR/ABL-positive cells,
as opposed to the CXCR4-regulatable Lyn and PI3-kinase
activities in BCR/ABL-negative control cells. Our results
demonstrate that the SDF-1 chemokine-regulated Lyn
pathway is a target for the BCR/ABL oncoprotein in trans-
formed hematopoietic cells. Thus, disruption of G protein–
coupled chemokine receptor signaling by the oncogenic ty-
rosine kinases, via Src-family kinase-dependent mechanism,
may be involved in the pathogenesis of human myeloid
leukemia. It is tempting to suggest that the BCR-ABL/Lyn
pathway is coupled to transcriptional regulation in hemato-
poietic cells. Future studies directed at the mechanisms by
which G protein–coupled chemokine receptors contribute
to cell transformation should prove informative, as will in-
vestigation of downstream transcriptional elements linked
to the BCR-ABL/Lyn pathway in hematopoietic cells. An
important goal is to determine whether analogous Src fam-
ily kinases-mediated mechanisms operate in different types
of precursor cells and G protein–coupled receptors. Identi-
fication of signaling molecules involved in the movement,
growth, and survival of normal progenitor and malignant
cells should lead to therapeutic targets of great efficiency, as
has been demonstrated in the case of STI571 and the inhi-
bition of BCR/ABL kinase in CML (42). Interestingly, a
dominant role for Lyn kinase in K562 cells selected for re-
sistance to STI571 was reported recently (60). Our present
results extend this new observation. They both strongly
suggest that combination of STI571 with inhibitors of Lyn
or/and PI3K may be considered as therapeutic alternative
that could circumvent resistance to STI571, particularly in
patients with advanced disease. Experiments to test this pos-
sibility are in progress in our laboratories.
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